Cargando…
Treatment of Prolactinoma
Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally been the primary treatment for the majority of prolactinomas, with surgery considered the second line. The aim of this review is...
Autores principales: | Inder, Warrick J., Jang, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413135/ https://www.ncbi.nlm.nih.gov/pubmed/36013562 http://dx.doi.org/10.3390/medicina58081095 |
Ejemplares similares
-
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022) -
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma
por: Fukuhara, Noriaki, et al.
Publicado: (2022) -
Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022) -
Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014) -
Treatment of Prolactinomas in Low-Income Countries
por: Kruljac, Ivan, et al.
Publicado: (2015)